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Panel: Research in context  
Evidence before this study  
A recent Cochrane review comparing letrozole with clomiphene followed by timed  
intercourse in infertile women with PCOS showed that the birth rate was higher in the 
letrozole group. Another Cochrane review demonstrated that there was no evidence that 
metformin improved live birth rates whether used alone or in combination with 
clomiphene. Berberine is a major active component of the Chinese herbal medicines 
Rhizoma coptidis, Cortex Phellodendri, and C. berberidis, and it has been used empirically 
for thousands of years in its herbal form to enhance fertility. When compared to 
metformin, berberine showed similar metabolic effects on improving insulin sensitivity 
and reducing hyperandrogenemia in women with PCOS. There are no studies assessing 
adjunctive therapy with letrozole in hopes of improving live birth rates among infertile 
women with PCOS.  
Added value of this study  
In terms of ovulation and live births, the combination of letrozole and berberine was not 
superior to letrozole alone, but both were superior to berberine alone in infertile women 
with PCOS. 
Implications of all the available evidence  
Improvement in the metabolic profile by berberine did not affect rates of ovulation, 
conception, pregnancy, and live birth achieved with letrozole in infertile women with 
PCOS. 
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ABSTRACT 
Background Letrozole leads to higher ovulation and live birth rates than 
clomiphene in infertile women with polycystic ovary syndrome (PCOS). Berberine, 
a major active component of the Chinese herbal medicines Rhizoma coptidis, 
Cortex phellodendri and C. berberidis, has even more profound metabolic effects 
than metformin. Our hypothesis was that a combination of letrozole and 
berberine would result in a higher live birth rate than letrozole or berberine alone 
in infertile women with PCOS. 
Methods This was a multicenter randomized double-blinded placebo-controlled 
trial in Mainland China. A total of 644 eligible women with PCOS defined by the 
Rotterdam criteria were randomized into one of the following three interventions 
for up to six menstrual cycles: letrozole plus berberine placebo (letrozole group), 
berberine plus letrozole placebo (berberine group), or the combination of 
letrozole and berberine (combination group).  
Findings The live birth rates were comparable between the letrozole and 
combination groups (36.3% vs. 34.4%, OR = 0.95, 95% CI = 0.73–1.23; p = 0.687), and 
these were higher than in the berberine group (22.0%)  (OR = 1.68, 95% CI = 1.23–
2.28, p = 0.001; OR = 1.57, 95% CI = 1.15–2.14, p = 0.004, respectively). Conception, 
pregnancy, and ovulation rates were similar for the letrozole and combination 
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groups, and these were higher than in the berberine group. There was one twin 
birth in the letrozole group, three twin births in the combination group, and none 
in the berberine group. Berberine was associated with constipation and nausea 
while letrozole was associated with fatigue and hot flashes. 
Interpretation For ovulation and live births, the combination of letrozole and 
berberine was not superior to letrozole alone, but both were superior to 
berberine alone. 
Funding National Public Welfare Projects for Chinese Medicine of China and the 
“11th–Five” Supportive Program of Science and Technology of China.  
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INTRODUCTION 
Polycystic ovary syndrome (PCOS) affects 5.6% of Chinese women 19–45 years of 
age, and the main clinical manifestations are oligo-anovulation and polycystic 
ovaries.1 It is the most common cause of anovulatory infertility. Although less 
pronounced than in Caucasians, Chinese women with PCOS also suffer from 
hyperandrogenism and hyperinsulinemia together with insulin resistance.2,3 Given 
the huge population and a lack of coverage for infertility treatment by the public 
health care system and insurance companies within mainland China, PCOS 
constitutes a considerable economic burden and source of emotional distress.4  
 
The first-line medical treatment for anovulatory infertility in women with PCOS is 
ovulation induction by clomiphene, an anti-estrogen. The drawbacks for 
clomiphene include a relatively low cumulative live birth rate together with higher 
multiple pregnancy rates than unassisted conception.5 Insulin-sensitizing agents 
such as metformin are commonly used as adjunct medication for women with 
PCOS. However, metformin alone is not superior to clomiphene or a combination 
of metformin and clomiphene.5 Recently letrozole, an aromatase inhibitor, has 
been shown to be superior to clomiphene for ovulation and live birth rates in 
infertile women with PCOS.6  
 
Berberine, a major active component of the Chinese herbal medicines Rhizoma 
coptidis, Cortex Phellodendri, and C. berberidis, has been prescribed empirically for 
the treatment of diarrhea, metabolic disorders, and infertility.4,7,8 Berberine is 
commonly used in China. A total of 0.8 billion 0.1 mg tablets were consumed at 
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the end of 2000 and 5.9 billion were consumed in 2013, and this is projected to 
reach 12 billion in 2015.9 It has been used for thousands of years in its herbal form 
to enhance fertility and recently as an extract combined with ovulation induction 
agents such as  clomiphene or letrozole to enhance their effectiveness. 4 
  
We previously demonstrated that berberine could alleviate the insulin resistance 
and androgen synthesis in insulin-resistant ovaries cultured in vitro and when we 
assessed its function in vivo.10,11 When compared to metformin, berberine showed 
similar metabolic effects on improving insulin sensitivity and reducing 
hyperandrogenemia, and berberine had additional effects on body composition 
and dyslipidemia in women with PCOS.12 Because of its favorable effects on these 
metabolic factors, berberine has the potential to complement letrozole in 
improving live birth rates among infertile women with PCOS. To our knowledge, 
this is the only study to investigate ovulation and live birth rates following the use 
of berberine in women with PCOS.  
 
We sought to determine the effectiveness of letrozole alone, berberine alone, and 
the combination of the two in achieving live births among infertile women with 
PCOS. Our primary hypothesis was that the combination of berberine and 
letrozole would result in significantly higher live birth rates than treatment with 
letrozole or berberine alone.13  
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METHODS 
Study Oversight 
This was a multicenter randomized double-blind placebo-controlled trial in 
Mainland China. Recruited participants were allocated randomly into one of the 
three groups in a ratio of 1:1:1. We previously reported details of the trial 
protocol,13 which was designed by the steering committee of the National Clinical 
Trial Base and approved prior to initiation by the State Administration of 
Traditional Chinese Medicine of the People’s Republic of China – the appointed 
scientific advisory board. The institutional review board at each participating 
center approved the protocol, and all participants gave written informed consent. 
It was first registered at http://www.chictr.org.cn/ in Chinese with identifier 
ChiCTR-TRC-0900 0376 on October 7, 2009 within China, and then registered at 
ClinicalTrials.gov with identifier NCT0111 6167 on April 27, 2010. 
 
 
Participants 
A total of 644 women were enrolled in 18 participating sites. Chinese women with 
PCOS attempting to get pregnant were eligible if they fulfilled the following 
criteria: (1) age between 20 and 40 years; (2) diagnosis of PCOS according to two 
of the three Rotterdam 2003 criteria,14 including oligo-ovulation or anovulation, 
clinical and/or biochemical signs of hyperandrogenism, and/or polycystic ovaries; 
(3) at least one open Fallopian tube and normal uterine cavity documented by 
hysterosalpingogram, sonohysterogram, or diagnostic laparoscopy within the 
past 3 years; (4) a male partner with sperm concentration of 15 million/mL and 
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motility of ≥40% in at least one ejaculate; and (5) at least 1 year of infertility. 
Subjects were excluded if they used hormonal drugs or other medications 
including Chinese herbal prescriptions in the past 3 months; had known severe 
organ dysfunction or mental illness; were pregnant, post-miscarriage, postpartum, 
or breastfeeding within the past 6 weeks; or had congenital adrenal hyperplasia, 
clinically suspected Cushing’s syndrome, or an androgen-secreting neoplasm. 
 
Randomization and Masking 
The randomization was performed through a web-based computer program 
(http://210.76.97.192: 8080/cjbyj) operated by an independent data center—the 
Institute of Basic Research in Clinical Medicine (IBRCM) of the China Academy of 
Chinese Medical Sciences. The randomization is stratified by the participating sites.  
Participants, investigators, physicians taking care of the participants, laboratory 
technicians, and data analyzers were blinded to the assignments. 
 
Procedures 
After spontaneous menses or withdrawal bleeding induced by progestin 
administration (medroxyprogesterone acetate [Provera, Pfizer Italia Srl 
Pharmaceutical Co, Ltd], 5 mg per day for 7 days), eligible patients were 
randomized into one of three interventions: (1) letrozole and berberine placebo 
(letrozole group), (2) berberine and letrozole placebo (berberine group), or (3) 
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letrozole and berberine (combination group). Each participant received a 
medication package on a monthly basis that consisted of a monthly supply of 
berberine capsules or placebo capsules and one or two packages of pills 
(letrozole or letrozole placebo, one package per month for the first three months, 
and two packages per month for the next three months). Berberine or berberine 
placebo were administrated orally at a daily dose of 1.5 g for 6 months. Patients 
received an initial dose of 2.5 mg (one tablet) of letrozole or one tablet of 
letrozole placebo on days 3–7 of the first three treatment cycles. This dose was 
increased to 5 mg of letrozole (two tablets) or two tablets of letrozole placebo on 
days 3–7 of the last three treatment cycles if not pregnant. Couples were 
instructed to have regular intercourse two to three times a week until becoming 
pregnant. Ovulation detection kits and intrauterine insemination were not used.  
 
Berberine and berberine placebo were produced by Renhetang Pharmaceutical 
Co, Ltd, China. Letrozole and letrozole placebo were produced by Jiangsu Hengrui 
Medicine Co, Ltd, China. Neither manufacturer had a financial role in the study. 
Fasting blood samples for assessment of metabolic and hormonal profiles were 
drawn at the baseline visit and at the end of the treatment visit at menstrual cycle 
days 3–7 and analyzed in the core laboratory at Harbin. The intra-assay and inter-
assay coefficients of variation of each assay were <10%. All baseline measures 
including assessment of liver and renal function were repeated at the end of the 
visits. Participants had monthly visits after menses to document a negative 
pregnancy test to avoid inadvertent exposure to letrozole and berberine during 
pregnancy. Once participants conceived, they were followed until a viable 
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intrauterine pregnancy sac was observed (fetal heart motion visualized on 
ultrasonography). They were then referred for antenatal care. Outcomes were 
tracked through regular interviews with midwives and abstractions of obstetric 
records.  
 
Outcomes 
The primary outcome was live birth.  Secondary outcomes included (1) Ovulation: 
Serum progesterone level >5 ng/ml on day 22 of each treatment cycle; (2) 
Conception: A positive serum level of human chorionic gonadotropin; (3) 
Pregnancy: An intrauterine pregnancy sac with fetal heart motion as determined 
by ultrasonography at around 8–10 weeks gestation; (4) Multiple pregnancy; (5) 
Pregnancy loss: Loss before 20 completed weeks of gestation; (6) Other 
pregnancy complications such as stillbirth, gestational diabetes mellitus, 
pregnancy-induced hypertension, and small for gestational age fetus; and (7) 
Adverse events from the study medication. Patients were asked to record adverse 
events and to report them to the coordinator at each visit. Serious adverse events 
were defined as events that were fatal or immediately life-threatening, that were 
severely or permanently disabling, or that required prolonged inpatient 
hospitalization; overdoses (intentional or accidental); congenital anomalies; or 
any event deemed to be serious by the site principal investigator at the study site.  
 
Statistical Analysis 
The sample size calculation was based on anticipated live birth rate. A previous 
meta-analysis suggested that the live birth rate using letrozole in women with 
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PCOS was about 22% during a 6-month intervention 13 and our study was designed 
and completed prior to the more recently published large randomized trial.6 We 
hypothesized that a combination of letrozole and berberine would increase the 
live birth rate from 22% to 30%. Accordingly, we estimated that a sample size of 
220 participants per group was required considering a 20% dropout, 90% power, 
and an alpha error of 0.05. On the basis of these assumptions, we needed to 
enroll 660 subjects for the study.  
 
All data entry, data management, and analyses were performed through a web-
based system (http://210.76.97.192: 8080/cjbyj) operated by IBRCM of the China 
Academy of Chinese Medical Sciences. 
 
Either a chi-square test or Fisher’s exact test was used at a two-sided significance 
level of 0.05 for testing differences among the three study groups for categorical 
variables. The Kruskal-Wallis was used to test differences among the three groups 
for continuous variables. If significant, a Mann–Whitney U-test was used to test 
differences between the groups. Kaplan-Meier analysis was used to compare time 
to live birth according to treatment groups, 5,6 body mass index (BMI), hirsutism 
scores, menstrual patterns, age, and previous infertility duration. Adverse events 
were categorized, and the percentage of patients experiencing adverse events 
and serious adverse events in each treatment arm were compared using chi-
square tests. All analyses were performed with the SAS software, version 9.2 (SAS 
Institute). Data were analyzed according to the intention-to-treat principle. 
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Role of the Funding Sources  
 The funding body of the study had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. The co-authors had full 
access to all the data in the study, and the corresponding author had final 
responsibility for the decision to submit for publication.  
 
RESULTS 
Owing to the expiration of the study drug (berberine and matching placebo), the 
data safety and monitoring board decided to stop enrollment after 644 patients 
were enrolled in November 2013. The flowchart of the study is shown in Figure 1. 
The number of subjects who withdrew from the study was 16 of 215 (7.4%) in the 
letrozole group, 25 of 214 (11.7%) in the berberine group, and 15 of 215 (7.0%) in the 
combination group (p = 0.16) (Fig. 1). Reasons for withdrawal were similar among 
the three groups (p = 0.16 for the three groups, p = 0.19 for lost to follow-up, p = 
0.88 for drop-out, p = 1.0 for protocol violations, and p = 0.33 for adverse events).  
 
There were no significant differences in the ages of the women, duration of 
infertility, BMI, waist/hip circumference, presence of hirsutism, menstrual pattern, 
ultrasound features of polycystic ovaries, or baseline hormonal profile among the 
three groups (Table 1). 
 
Wu, et al. 14 
A total of 199 live births occurred, including 195 singletons and four sets of twins. 
The rate of live births was comparable between the letrozole and combination 
groups (36.3% vs. 34.4%, OR = 0.95, 95% CI = 0.73–1.23; p = 0.687), and both were 
significantly higher than the berberine group (22%) (OR = 1.68, 95% CI = 1.23–2.28, 
p= 0.001; OR = 1.57, 95% CI = 1.15–2.14, p = 0.004, respectively) (Table 2 and Fig. 2A).  
Birth weight among live births was comparable among the three groups. There 
were three twin live births in the combination group, one in the letrozole group, 
and none in the berberine group. 
 
Independent of treatment, subjects with age less than 33 years had significantly 
higher rates of live births than did women whose age was greater than 33 years (p 
= 0.018, Fig. 2D). There was no significant difference in live birth rate stratified by 
BMIs  (p = 0.782, Fig. 2B), menstrual cycle pattern  (p = 0.689,Fig. 2C), hirsutism or 
duration of infertility (data not shown).  
 
The rates of ovulation, conception, and pregnancy also were similar in the 
combination and letrozole groups, and these were significantly higher than those 
in the berberine group. As for fecundity among subjects who ovulated, the 
letrozole and combination groups were superior to the berberine group with 
regard to conception rates and/or pregnancy rates. The three groups had 
comparable rates of pregnancy loss after conception.  
 
No serious adverse events occurred during the intervention in any of the three 
groups. Berberine was associated with a significantly higher incidence of 
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constipation and nausea while letrozole was associated with a significantly higher 
incidence of fatigue and hot flashes. There were no significant differences among 
the three groups with regard to rates of total cases of adverse events (37.0%, 
48.0%, and 45.5% for the letrozole, berberine, and combination groups, 
respectively) or for cases of serious adverse events including ectopic pregnancies, 
pregnancy loss during the second trimester, or preterm labor (21.4%, 20.8%, and 
23.5%, respectively) (Table 3).  
 
During pregnancy, the most common complication was pregnancy-induced 
hypertension, followed by gestational diabetes, threatened abortion, and 
premature rupture of membranes. There were no significant differences among 
the three treatment groups for these events. Two major congenital anomalies 
were reported, but no autopsies were performed. One fetal abnormality in the 
letrozole group was found during ultrasound examination at gestational week 16, 
resulting in termination of the pregnancy. Another abnormality resulted in an 
infant death on day 31 after birth in the combination group, but the cause of 
death was unknown.  
 
DISCUSSION 
Our findings do not support the hypothesis that a combination of letrozole and 
berberine is superior to letrozole alone for achieving live birth in infertile women 
with PCOS. The rates of ovulation, conception, pregnancy, and live birth were 
comparable between the letrozole and combination groups. These endpoints 
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were significantly higher in both groups with letrozole than those in the berberine 
alone group. We found that the higher ovulation rate per cycle account for the 
superiority of this cumulative live birth rate for letrozole or combination 
treatment compared to berberine alone.  
 
The use of insulin-sensitizing agents such as metformin in women with PCOS 
undergoing ovulation induction has been widely studied. A Cochrane review 15 
showed that there was no evidence that metformin improved live birth rates, 
whether used alone or in combination with clomiphene. Therefore, the role of 
metformin in improving reproductive outcomes in women with PCOS appears to 
be limited. Berberine, an active ingredient from Chinese medicinal herbs, has 
multiple biological activities and pharmacological effects in several metabolic 
diseases such as type 2 diabetes mellitus, hyperlipidemia, and nonalcoholic fatty 
liver disease.7,8,16 A systemic review and meta-analysis for berberine in the 
treatment of type 2 diabetes mellitus demonstrated comparable glycemic control 
with other oral hypoglycemic agents. However, berberine also showed an anti-
dyslipidemic effect.7 The relevant targets of berberine might link to the insulin 
pathway, adenosine monophosphate-activated protein kinase signaling, the gut 
environment, and hepatic lipid transportation. 16  
 
In a study 12 comparing berberine and metformin, 89 Chinese women with PCOS  
and insulin resistance were randomized into one of three treatment groups: 
berberine and cyproterone acetate, metformin and cyproterone acetate, or 
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placebo and cyproterone acetate for three months. Berberine showed similar 
restoration of insulin sensitivity and reduction of hyperandrogenemia when 
compared with metformin. Berberine also appeared to have a greater effect on 
changes in body composition and dyslipidemia in PCOS patients.  
 
Our results showed that ovulation and live birth rates for a combination of 
letrozole and berberine were comparable to letrozole alone. This implied that 
improvement in the metabolic profile by berberine did not affect the ovulation or 
live birth rates achieved with letrozole. We did not measure insulin sensitivity 
before and after exposure to the study medication in the present study. We did 
not find a significant difference in live birth rate stratified by BMI, hirsutism score, 
menstrual patterns, or duration of infertility. Our results contrasted with those 
from a study conducted in the Netherlands,17 where BMI, age, free androgen 
index, and cycle history were all associated with live birth in women with PCOS 
receiving clomiphene. In the population-based Northern Finland Birth Cohort 1966 
study,18 previous oligo-amenorrhea and/or hirsutism and obesity were both found 
to be independently associated with decreased fecundity. These differences 
might be related to the distinct phenotypes of PCOS in which Chinese women are 
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more likely to have irregular menstrual cycles and less hyperandrogenism than 
Caucasians women. 1,2   
 
Letrozole has a shorter half-life than clomiphene leading to a shorter exposure 
during implantation and early fetal development, and, therefore, a low theoretical 
risk of congenital anomalies in the offspring.6,19 There has been significant 
concern for congenital anomalies since the introduction of letrozole for use in 
inducing ovulation. In this trial, we reported one fetal abnormality in the letrozole 
group, one neonatal death in the combination group, and no abnormalities in the 
berberine group. However, our study was underpowered to detect a significant 
difference for rare but potentially serious adverse events. In the PCOS II trial,6 
Legro et al found four major congenital anomalies in the letrozole group and one 
in the clomiphene group. There was no pattern to the four major anomalies with 
letrozole, implying they were random events. The rate of congenital anomalies in 
the present study is below what has been reported in other studies. 20 
 
In the present study, the use of berberine alone achieved a 36% ovulation rate, 
similar to metformin, and a 22% live birth rate similar to clomiphene after 6 
months of use.5 To the best of our knowledge, these is the first study to show the 
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effect of berberine alone on the ovulation and live birth rates in women with 
PCOS. However, we cannot make conclusions regarding efficacy because 
berberine was not compared to a placebo or to no treatment. Studies comparing 
clomiphene and berberine for ovulation induction have not yet been performed. 
 
One of the limitations of this study was its early termination because of the 
expiration of the study drug (berberine and its placebo). However, the absolute 
difference (12–14%) in live-birth rates for the original two primary comparisons of 
letrozole to berberine in this trial was greater than the projected 8%; hence, the 
unexpected reduction to 644 participants still provided adequate power (≥90%) 
for the study. Other limitations included not all subjects having pelvic sonograms 
to assess for polycystic ovaries and the inclusion of subjects with regular cycles. 
The major strength of this study is that it was a large multi-center double blind 
trial with close monitoring of adverse events and serious adverse events and 
tracking of live birth in line with our recent Harbin consensus. 21  
 
In summary, a combination of letrozole and berberine was not superior to 
letrozole alone in terms of live birth and ovulation, but both were superior to 
berberine alone in infertile women with PCOS.    
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CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 4 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 6 
2b Specific objectives or hypotheses 7 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 8 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons no 
Participants 4a Eligibility criteria for participants 8 
4b Settings and locations where the data were collected 9 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
10 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
11 
6b Any changes to trial outcomes after the trial commenced, with reasons no 
Sample size 7a How sample size was determined 12 
7b When applicable, explanation of any interim analyses and stopping guidelines no 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 9 
8b Type of randomisation; details of any restriction (such as blocking and block size) 9 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
9 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
9 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 9 
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assessing outcomes) and how 
11b If relevant, description of the similarity of interventions  
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 12 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 12 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
13  
and Figure 1 
13b For each group, losses and exclusions after randomisation, together with reasons 13 
Recruitment 14a Dates defining the periods of recruitment and follow-up 13 
14b Why the trial ended or was stopped 13 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 14,  
Table 1 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
14 
and Table 1 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
14 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 14 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
14 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 15 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 19 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 20 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 20 
Other information  
Registration 23 Registration number and name of trial registry 8, China 
clinical trial 
registry and 
clinicaltrials.g
ov 
Protocol 24 Where the full trial protocol can be accessed, if available 7,publication 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 13,22 
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*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
Figure 1: Enrollment and outcomes 
 
 
 
Figure 2: Kaplan–Meier curves for live births according to treatment group (Panel 
A), body-mass Index (BMI) (Panel B), menstrual pattern (Panel C) and age (Panel 
D). 
 
 
Table 1. Baseline Characteristics  
Biometric features 
Letrozole Group 
(N = 215 ) 
Berberine Group 
(N = 214 ) 
Combination Group 
(N = 215 ) 
Age of women (yr)a 27.8 ± 3.6* 27.8 ± 3.7 27.8 ± 3.6 
Body mass index (kg/m2)a 24.8 ± 4.5 24.5 ± 4.1 25.1 ± 5.0 
Waist circumference (cm ) a 83.5 ± 10.9 82.7 ± 11.8 83.1 ± 11.8 
Hip circumference (cm) a 98.1 ± 11.4 97.7 ± 11.8 97.9 ± 10.9 
WHRa 0.85 ± 0.08 0.85 ± 0.08 0.85 ± 0.07 
Hirsutism (Ferriman-Gallwey ≥5)b  78/202 (38.6) 76/201 (37.8) 60/209 (28.7) 
Menstrual patternb,c    
Oligomenorrhea  126/201 (62.7) 116/193 (60.1) 121/198 (61.1) 
Regular menses 75/201 (37.3) 77/193 (39.9) 77/198 (38.9) 
Duration of infertility (months)a 32.7 ± 24.0 28.5 ± 21.6 29.8 ± 21.3 
Previous infertility therapyb 178 (82.8) 180 (84.1) 185 (86.0) 
Traditional Chinese Medicine 107/178 (60.1) 112/180 (62.2) 110/185 (59.5) 
Ovulation drugs 121/178 (68.0) 109/180 (60.6) 107/185 (57.8) 
Assisted Reproductive Technology 9/178 (5.1) 11/180 (6.1) 12/185 (6.5) 
Other therapies 8/178 (4.5) 8/180 (4.4) 6/185 (3.2) 
Previous pregnancyb     
Conception 67 (31.2) 62 (29.0) 80 (37.2) 
Live birth 9 (4.2) 7 (3.3) 7 (3.3) 
Miscarriage  13 (6.1) 16 (7.5) 26 (12.1) 
Termination of pregnancy  48 (22.3) 43 (20.1) 64 (29.8) 
Ultrasonographic findings    
Polycystic ovary morphology — no. (%) # 104/151 (68.9) 113/153 (73.9) 98/155 (63.2) 
Ovarian volume (cm3) a    
Left ovary 10.3 ± 6.8 9.5 ± 7.9 11.0 ± 6.8 
Right ovary 11.0 ± 6.3 10.2 ± 6.4 11.6 ± 7.4 
Fasting serum levelsa    
Testosterone (nmol/L) 1.6 ± 0.8 1.4 ± 0.7 1.4 ± 0.7 
Estradiol (pmol/L) 213.9 ± 206.3 244.0 ± 252.4 228.8 ± 233.0 
Free androgen indexd 5.0 ± 4.8 5.3 ± 6.3 5.1 ± 5.8 
FSH (mIU/L) 5.7 ± 2.1 5.3 ± 1.8 5.5 ± 1.9 
LH (mIU/L) 10.9 ± 6.7 10.0 ± 6.5 10.4 ± 6.1 
LH/FSH  2.0 ± 1.1 1.9 ± 1.2 1.9 ± 1.1 
SHBG (nmol/L) 48.1 ± 31.1 47.6 ± 32.9 42.6 ± 28.3 
Prolactin (mIU/L) 318.0 ± 160.9 311.3 ± 168.4 296.7 ± 155.8 
aData are given in means ± standard deviation 
bData are given in number (%)  
cMissing information in some subjects 
dThe free androgen index was calculated according to the following formula: (total testosterone 
[nanomoles per liter] /SHBG [nanomoles per liter]) × 100. 
 
Table 2. Live birth and other fecundity outcomes 
Outcomes  
number (%) 
Letrozole 
Group 
(N = 215) 
Berberine 
Group 
(N = 214) 
Combination 
Group 
(N = 215) 
Odds Ratio 
Between Combination 
and Letrozole 
p-value 
Odds Ratio 
Between Combination 
and Berberine 
p-value 
Odds Ratio 
Between Letrozole 
and Berberine 
p-value 
 no. /total no. (%) OR (95% CI)  OR (95% CI)  OR (95% CI)  
Primary outcomes          
Live birth 78/215 (36.3) 47/214 (22.0) 74/215 (34.4) 0.95 (0.73–1.23) 0.687   1.57 (1.15–2.14) 0.004 1.68 (1.23–2.28) 0.001 
  Singleton live birth 77/78 (98.7) 47/47 (100) 71/74 (95.9) 0.97 (0.92–1.03) 0.357 0.96 (0.92–1.01) 0.28   0.99 (0.96–1.01) 1.000 
Twin live birth 1/78 (0.1) 0/47 (0) 3/74 (0.4) 3.16 (0.34–29.72) 0.357 4.48 (0.24–84.82) 0.28 1.82 (0.08–43.85) 1.000 
Birth weight (gram) 3463 ± 575 3542 ± 399 3484 ± 504 21.20 (–177.16–219.57) 0.845 –58.23 (–248.84–132.38) 0.246 –79.43 (–282.07–123.20) 0.216 
Secondary outcomes          
Ovulation 473/796 (59.4) 
 
302/831 (36.3) 486/797 (61.0) 1.03 (0.95–1.11) 0.526   1.68 (1.51–1.87) <0.0001    1.64 (1.47–1.82) <0.0001 
  Conception 98/215 (45.6) 61/214 (28.5) 105/215 (48.8)    1.07 (0.88–1.31) 0.499 1.71 (1.33–2.21) <0.0001 1.60 (1.24–2.07) 0.0003 
     Immediate loss to follow up 3/98（3.1） 0 4/105（3.8） 1.24 (0.29–5.42) 1.000 – – – - 
  Pregnancy 84/215 (39.1) 48/214 (22.4) 81/215 (37.7) 0.96 (0.76–1.23) 0.766 1.68 (1.24–2.27) 0.0006 1.741 (1.29–2.35) 0.0002 
  Singleton 83/84 (98.8) 48/48 (100.0) 78/81 (96.3)   0.97 (0.93–1.02) 0.361 0.96 (0.92–1.01) 0.294   0.990.97–1.01) 1.000 
  Twins 1/84 (1.2) 0 3/81 (3.7)   3.11 (0.33–29.30) 0.361 – – – - 
  Pregnancy loss 17/98 (17.4) 14/61 (23.0) 27/105 (25.7) 1.48 (0.86–2.55) 0.148 1.12 (0.64–1.97) 0.691 0.76 (0.40–1.42) 0.386 
    In the first trimester 13/98 (13.2) 14/61 (23.0) 24/105 (22.9) 1.72 (0.93–3.19) 0.077 0.996 (0.56–1.78) 0.989 0.58 (0.29–1.15) 0.114 
    In the second trimester 4/98 (4.1) 0 3/105 (2.9) 0.70 (0.16–3.05) 0.714 – – – - 
Fecundity among ovulated cycles              
   Conception 98/473 (20.7) 61/302 (20.2) 105/486 (21.6) 1.05 (0.77-1.44) 0.737 1.09 (0.76-1.55) 0.638 1.03 (0.72-1.48) 0.861 
   Pregnancy 84/473 (17.5) 48/302 (15.9) 81/486 (16.1) 0.94 (0.71-1.24) 0.654 1.05 (0.76- 1.45) 0.776 1.13 (0.76-1.66) 0.549 
   Live birth 78/473 (16.3) 47/302 (15.6) 74/486 (14.6)   0.92 (0.69-1.24) 0.592   0.98 (0.70-1.37) 0.899 1.06 (0.71-1.57) 0.791 
Fecundity among subjects who ovulated          
Conception 98/188 (52.1) 61/147 (41.5) 105/184 (57.1) 1.09 (0.91–1.32) 0.339 1.38 (1.09–1.73) 0.005 1.26 (0.99–1.59) 0.053 
Pregnancy 84/188 (44.2) 48/147 (32.7) 81/184 (42.4) 0.99 (0.78–1.24) 0.898 1.35 (1.02–1.79) 0.035 1.37 (1.03–1.81) 0.025 
Live birth 78/188 (41.0) 47/147 (32.0) 74/184 (38.6) 0.97 (0.76–1.24) 0.803 1.26 (0.94–1.69) 0.122 1.30 (0.97–1.74) 0.074 
Ovulation was defined as a serum progesterone level according to the standard of the local lab (minimum value of luteal phase) or more than 5 ng/ml. Conception was defined as any positive serum level of human chorionic 
gonadotropin. Pregnancy was defined as an intrauterine pregnancy sac with fetal heart motion as determined by ultrasonography. Live birth was defined as the delivery of a viable infant.; a means ± standard deviation 
 
 
 
 
 
Table 3: Adverse events during study medication, pregnancy, and neonatal period  
Adverse Events 
Letrozole Group 
(N = 215) 
Berberine Group 
(N = 214) 
Combination Group 
(N = 215) 
Serious adverse event from study medication 0/215 (0) 0/214 (0) 0/215 (0) 
Other adverse events  
 Constipation 10/215 (4.7) 26/214 (12.1)* 12/215 (5.6) 
 Nausea  13/215 (6.0) 34/214 (15.9)* 26/215 (12.1) 
 Diarrhea 13/215 (6.0) 5/214 (2.3) 5/215 (2.3) 
 Hot flashes 21/215 (9.8) 6/214 (2.8)* 19/215 (8.8) 
 Fatigue  17/215 (7.9) 5/214 (2.3)* 18/215 (8.4) 
Serious events during pregnancy 
First trimester    
 Ectopic pregnancy 2/84 (2.4) 2/48 (4.2) 2/81 (2.5) 
Second and third trimesters    
 Pregnancy loss after 12 weeks 4/84 (4.8) 0/48 (0) 3/81 (3.7) 
 Pre-eclampsia  4/84 (4.8) 6/48 (12.5) 7/81 (8.6) 
 Gestational diabetes  3/84 (3.6) 3/48 (6.3) 7/81 (8.6) 
 Preterm labor 2/84 (2.4) 0/48 (0) 2/81 (2.5) 
 Premature rupture of membranes  5/84 (6.0) 1/48 (2.1) 2/81 (2.5) 
Serious event in fetus and infant    
 Fetal abnormality 1/84 (1.2) 0/48 (0) 0/48 (0) 
 Neonatal death  0/78 (0) 0/47 (0) 1/74 (1.4) 
 
Data given in number (%) 
*p < 0.05 vs. other two groups. 
 
 
  
